27 Oct Chewing Loading-Dose of Ticagrelor Enhanced Platelet Inhibition in Heart Attack Patients
MedicalResearch.com Interview with:
Dr. Asher
Elad Asher, M.D, M.H.A
Interventional Cardiologist,
Director Intensive Cardiac Care Unit
Deputy Director Heart Institute
Assuta Ashdod Medical Center
MedicalResearch.com: What is the background for this study?
Response: Dual antiplatelet therapy represents the standard care for treating ST elevation myocardial infarction (STEMI) patients. Given the higher risk of peri-procedural thrombotic events in patients undergoing primary percutaneous coronary intervention (PPCI), there is a need to achieve inhibition of platelet aggregation (IPA) more promptly. Although chewing ticagrelor has been shown to be more efficient for IPA in stable coronary disease and in patients with acute coronary syndrome (ACS)/non-ST elevation myocardial infarction (NSETMI), there are no studies that have specifically assessed the efficacy and safety of chewing ticagrelor in STEMI patients. Therefore, the aim of our study was to investigate whether chewing ticagrelor (180mg) loading dose is associated with more favorable platelet inhibitory effects compared with the conventional way of swallowing whole tablets loading dose in STEMI patients undergoing PPCI.
MedicalResearch.com: What are the main findings?
Response: We found that in STEMI patients undergoing PPCI, chewing ticagrelor (180mg) loading dose was associated with enhanced platelet inhibition compared with standard ticagrelor loading dose administration. Notably, enhanced platelet inhibition with chewing ticagrelor was observed as early as 30 min after drug administration.
MedicalResearch.com: What should clinicians and patients take away from your report?
Response: Chewing ticagrelor (180mg) loading dose in STEMI patients is feasible and facilitates better early platelet inhibition compared with standard oral loading dose.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Response: It will be important for future research to investigate if our pharmacodynamics findings translate into improved clinical outcomes in STEMI patients.
No disclosures
MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.
Citation:
Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.
[wysija_form id=”1″]
Last Updated on October 27, 2017 by Marie Benz MD FAAD